Vanda Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vanda Pharmaceuticals, Inc.
The merger closed in May, so the second quarter earnings report will be the first presentation of the combined company’s performance and outlook.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
After a prior failure in treating anxiety, the company believes the glutamate modulator showed signs of efficacy in obsessive-compulsive disorder that are worth pursuing, including at a higher dose.
Company specializing in trading upfront cash for downstream earnings makes its public debut with largest IPO of 2020, and the second largest ever in biopharma.
- Specialty Pharmaceuticals